Abstract
A series of 19 isonicotinic acid hydrazide derivatives has been synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv using alamar blue susceptibility test. The synthesized compounds inhibit Mycobacterium tuberculosis H37Rv strain with minimum inhibitory concentration ranging from (0.00014-0.01174 mM). Among all synthesized compounds seven derivatives 2a, 2b, 2e, 2h, 2l, 2m and 2q were more potent than isoniazid and the compound 2q emerged as the most potent derivative, being more effective than isoniazid with an (MIC 0.00023 mM) in vitro. The results demonstrated the potential and importance of developing new isoniazid derivatives against Mycobacterium infections.
Keywords: Isonicotinoyl hydrazones, Mycobacterium tuberculosis H37Rv, Antitubercular activity, IR, 1H NMR, C-NMR, hydrazide Derivatives, Antitubercular Agents, Tuberculosis, Mycobacterium tuberculi, amikacin, capreomycin, HIV-1 seropositive, chemotherapy, chromosomal mutation, isonicotinoyl hydrazone
Letters in Drug Design & Discovery
Title: Synthesis, Characterization of (E)-N'-(substituted-benzylidene)isonicotinohydrazide Derivatives as Potent Antitubercular Agents
Volume: 8 Issue: 6
Author(s): Manav Malhotra, Rajiv Sharma, Vikramdeep Monga, Aakash Deep, Kapendra Sahu and Abdul Samad
Affiliation:
Keywords: Isonicotinoyl hydrazones, Mycobacterium tuberculosis H37Rv, Antitubercular activity, IR, 1H NMR, C-NMR, hydrazide Derivatives, Antitubercular Agents, Tuberculosis, Mycobacterium tuberculi, amikacin, capreomycin, HIV-1 seropositive, chemotherapy, chromosomal mutation, isonicotinoyl hydrazone
Abstract: A series of 19 isonicotinic acid hydrazide derivatives has been synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv using alamar blue susceptibility test. The synthesized compounds inhibit Mycobacterium tuberculosis H37Rv strain with minimum inhibitory concentration ranging from (0.00014-0.01174 mM). Among all synthesized compounds seven derivatives 2a, 2b, 2e, 2h, 2l, 2m and 2q were more potent than isoniazid and the compound 2q emerged as the most potent derivative, being more effective than isoniazid with an (MIC 0.00023 mM) in vitro. The results demonstrated the potential and importance of developing new isoniazid derivatives against Mycobacterium infections.
Export Options
About this article
Cite this article as:
Malhotra Manav, Sharma Rajiv, Monga Vikramdeep, Deep Aakash, Sahu Kapendra and Samad Abdul, Synthesis, Characterization of (E)-N'-(substituted-benzylidene)isonicotinohydrazide Derivatives as Potent Antitubercular Agents, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906866
DOI https://dx.doi.org/10.2174/157018011795906866 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Therapy in Sarcoidosis, the Role of Existing Drugs and Future Medicine
Inflammation & Allergy - Drug Targets (Discontinued) Selection of Targets for Drug Development Against Protozoan Parasites
Current Drug Targets Novel Drug Delivery Magnetite Nano-systems Used in Antimicrobial Therapy
Current Organic Chemistry Pleural Involvement in Systemic Disorders
Current Drug Targets - Inflammation & Allergy Development of 'S', 'N' Heterocycles as Antimycobacterials Targeting Fatty Acid Biosynthesis
Current Computer-Aided Drug Design Plasmid-Mediated Muscle-Targeted Gene Therapy for Circulating Therapeutic Protein Replacement: A Tale of the Tortoise and the Hare?
Current Gene Therapy Applications of Docking and Molecular Dynamic Studies on the Search for New Drugs Against the Biological Warfare Agents Bacillus anthracis and Yersinia pestis
Current Computer-Aided Drug Design Mutagenicity of N-oxide Containing Heterocycles and Related Compounds: Experimental and Theoretical Studies
Current Topics in Medicinal Chemistry MiR-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer SW480 Cells <i>via</i> Targeting STAT3
Recent Patents on Anti-Cancer Drug Discovery Mechanism(s) Involved in Opioid Drug Abuse Modulation of HAND
Current HIV Research Lipid-Based Nanocarriers for Cutaneous Leishmaniais and Buruli Ulcer Management
Current Pharmaceutical Design Synthesis and Antimycobacterial Activity of 2-aryl-3-(arylmethyl)-1,3-thiazolidin-4-ones
Letters in Drug Design & Discovery Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Macrolide Resistance Based on the Erm-mediated rRNA Methylation
Current Drug Targets - Infectious Disorders Biomarkers Associated with Vulnerable Atheromatous Plaque
Current Medicinal Chemistry Development of Antibacterial Drugs by Targeting Toll-Like Receptors
Current Topics in Medicinal Chemistry Dendritic Cells: A Double-Edge Sword in Atherosclerotic Inflammation
Current Pharmaceutical Design Renal & Ocular Targets for Therapy in Wegeners Granulomatosis
Inflammation & Allergy - Drug Targets (Discontinued) Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Multilocular Thymic Cyst in a Patient with Untreated HIV/AIDS: Case Report and Review of the Literature
Current HIV Research